LOXL1 and glaucoma: Several compounds that target ECM synthesis and degradation pathways, such as decorin, lysyl oxidase-like 1 (LOXL1), and matrix metalloproteinases (MMPs), have been investigated for their potential as anti-fibrotic therapeutics in glaucoma (Nikhalashree et al., 2022; Schlotzer-Schrehardt and Zenkel, 2019; Weinreb et al., 2020).